You got a Talquetamab dose and your body started talking. You must be wondering what it is but the fact is Talquetamab is not a smooth journey in every patient. Some may experience fever associated with unusual tiredness and changes in heart rate. These are the symptoms not to be neglected. Let’s understand the clinical signs while you are on Talquetamab.
Patients researching Talquetamab availability in India should also understand the potential risks associated with treatment, including cytokine release syndrome (CRS).
How are Talquetamab and CRS connected?
Talquetamab is a bispecific GPRC5D-directed CD3 T-cell engager used to treat multiple myeloma who have already received at least four treatment regimens including proteasome inhibitor, an immunomodulatory, an anti-CD38 monoclonal antibody to treat multiple myeloma, and in cases where patient’s cancer has come back or did not respond to prior treatment. It is a T-cell bispecific antibody which binds to GPRC5D to one arm and also to CD3 on T-cells on the other arm simultaneously. GPRC5D is a surface antigen (protein) present on the surface of myeloma cells. When Talquetamab makes the union of myeloma cells and T cells, the immune system is activated and the GPRC5D is targeted, which results in the destruction of myeloma cells.
During this course of Talquetamab, release of inflammatory cytokines occurs due to activation of the immune system, hence the name ‘cytokine release syndrome. Cytokines are proteins that are part of a healthy immune system that helps control the growth and activity of blood cells and immune cells but when the amount of cytokines starts to increase, it causes inflammation leading to life-threatening situations.
For more information, explore Talvey Named Patient Program: Accessing Talvey Through a Regulated Pathway to understand the medicine access process and relevant requirements.
Role of premedications to control CRS
Ensure to administer the following pretreatment medications 1 to 3 hours before each dose of Talquetamab in the step-up dosing schedule to reduce the risk of CRS. The following are the different types of premedications:
- Corticosteroid (oral or intravenous dexamethasone, 16 mg or equivalent)
- Antihistamines (oral or intravenous diphenhydramine, 50 mg or equivalent)
- Antipyretics (oral or intravenous acetaminophen, 650 mg to 1,000 mg or equivalent)
Administration of pretreatment medications may be required for subsequent doses for patients who repeat doses within the Talquetamab step-up dosing schedule due to dose delays or for patients who experienced CRS.
For more information about preparing for treatment, read our guide to Talvey treatment preparation and access in India.
Why can CRS still happen?
- Premedications don’t completely prevent cytokine response but reduce the inflammatory symptoms. This don’t mean the premedications fsiled but this kind of prevention may lowers the severity of the condition.
- The intensity of immune system of one patient is not be same as the other.
- Step-up dosing of Talquetamab also reduces the CRS risk by slowly increasing the dosage amount but this can also not stop from CRS occurrence.
Symptoms of CRS and its management
Symptoms of CRS varies depending on the type of severity. The intensity of this severity is classified into four categories. One may experience temperature changes in all types of severity but fever may not always be present concurrently with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anticytokine therapy (e.g., corticosteroids).
Grade 1:
In the mild type of CRS, the temperature of the patient taking Talquetamab may be above or equal to 100.4°F (38°C). Withhold Talquetamab until CRS resolves. Administer pretreatment medication prior to next dose.
Grade 2:
In grade 2 type of CRS, temperature ≥100.4°F (38°C) with either hypotension responsive to fluids and not requiring vasopressors, or oxygen requirement of low-flow nasal cannulad or blow-by.
Withhold Talquetamab until CRS resolves. Administer pretreatment medications prior to next dose. Patients should be hospitalized for 48 hours following the next dose.
Grade 3:
The symptoms of grade3 type are either increase of temperature above 100.4°F (38°C) or equal to it and either hypotension requiring one vasopressor, with or without vasopressin, or oxygen requirement of high-flow nasal cannulas, facemask, non-rebreather mask, or Venturi mask.
Treatment plan changes with change in duration. If the duration is less than 48 hours, withhold Talquetamab until CRS resolves. Provide supportive therapy, which may include intensive care. Administer pretreatment medications prior to the next dose. Patients should be hospitalized for 48 hours following the next dose. In cases where the duration takes more than 48 hours, permanently discontinue the treatment and provide supportive therapy, which may include intensive care.
Grade 4:
In grade 4, temperature ≥100.4°F (38°C) with either hypotension requiring multiple vasopressors (excluding vasopressin).or, oxygen requirement of positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation, and mechanical ventilation), the treatment is same as done for the cases with duration more than 48 hours in grade 3 patients.
Patients researching how to Buy Talquetamab in India should consult their treating healthcare professional and verify applicable prescription and regulatory requirements before making medicine-access arrangements.
Share this content with your loved ones who are in need of it if you find it useful. Follow 24/7QualityMeds for more updates.
